Compare Hafnia Limited Common Shares (HAFN) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hafnia Limited Common Shares vs Johnson & Johnson — how do they compare? Hafnia Limited Common Shares trades at $10.13 (market cap $5.67B), while Johnson & Johnson trades at $258.16 (market cap $611.90B). The key difference: Johnson & Johnson is far larger — about 107.9× Hafnia Limited Common Shares's market cap, and Hafnia Limited Common Shares pays the higher dividend (10.44%). Which is the better fit depends on your goals — on Pluang, investors hold Hafnia Limited Common Shares for 0 Days and Johnson & Johnson for 129 Days on average.
| HAFN | JNJ | |
|---|---|---|
Market Cap | $5.67B | $611.90B |
Volume | 3,240,007 | 9,651,904 |
Sector | Industrials | Health |
52-Week High | $10.92 | $278.43 |
52-Week Low | $5.21 | $186.00 |
Typical Hold Time | 0 Days | 129 Days |
Enterprise Value | $6.29B | $640.18B |
Dividend Yield | 10.44% | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.
Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.
Johnson & Johnson (JNJ) trades at $248.61, down 5.73% in the last session, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with $2.59 EPS versus $2.52 expected, continuing a trend of three consecutive quarterly beats. JNJ maintains robust profitability with 67.91% gross margins and 21.48% net income margins, supported by $94.19B in 2025 revenue and $26.80B net income.
Analyst consensus remains positive with 52.5% buy ratings and a $282.53 price target, representing 13.6% upside potential. Key risks include patent cliffs affecting pharmaceutical revenue and increasing debt-to-asset ratio reaching 24.06% in 2025. The company's diversified healthcare portfolio and strong dividend history provide stability, while new drug launches like Icotyde offer growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hafnia Limited Common Shares
Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.
Read more on HAFN →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
